Reviva Pharmaceuticals (RVPH) Competitors $0.42 -0.01 (-2.26%) As of 11:14 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RVPH vs. VTGN, ORMP, ARTV, XBIT, ENTX, MIST, CABA, QNCX, JMAC, and EXOZShould you be buying Reviva Pharmaceuticals stock or one of its competitors? The main competitors of Reviva Pharmaceuticals include VistaGen Therapeutics (VTGN), Oramed Pharmaceuticals (ORMP), Artiva Biotherapeutics (ARTV), XBiotech (XBIT), Entera Bio (ENTX), Milestone Pharmaceuticals (MIST), Cabaletta Bio (CABA), Quince Therapeutics (QNCX), Maxpro Capital Acquisition (JMAC), and eXoZymes (EXOZ). These companies are all part of the "pharmaceutical products" industry. Reviva Pharmaceuticals vs. Its Competitors VistaGen Therapeutics Oramed Pharmaceuticals Artiva Biotherapeutics XBiotech Entera Bio Milestone Pharmaceuticals Cabaletta Bio Quince Therapeutics Maxpro Capital Acquisition eXoZymes Reviva Pharmaceuticals (NASDAQ:RVPH) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability. Does the media refer more to RVPH or VTGN? In the previous week, VistaGen Therapeutics had 5 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 6 mentions for VistaGen Therapeutics and 1 mentions for Reviva Pharmaceuticals. VistaGen Therapeutics' average media sentiment score of 0.00 beat Reviva Pharmaceuticals' score of -1.00 indicating that VistaGen Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Reviva Pharmaceuticals Negative VistaGen Therapeutics Neutral Which has stronger valuation & earnings, RVPH or VTGN? Reviva Pharmaceuticals has higher earnings, but lower revenue than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReviva PharmaceuticalsN/AN/A-$29.92M-$0.79-0.53VistaGen Therapeutics$490K180.07-$51.42M-$1.66-1.78 Do analysts prefer RVPH or VTGN? Reviva Pharmaceuticals presently has a consensus price target of $9.00, suggesting a potential upside of 2,047.97%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Reviva Pharmaceuticals is more favorable than VistaGen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Reviva Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29VistaGen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of RVPH or VTGN? 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are owned by institutional investors. 27.2% of Reviva Pharmaceuticals shares are owned by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is RVPH or VTGN more profitable? Reviva Pharmaceuticals has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -6,777.08%. Reviva Pharmaceuticals' return on equity of 0.00% beat VistaGen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Reviva PharmaceuticalsN/A N/A -302.31% VistaGen Therapeutics -6,777.08%-58.88%-52.38% Which has more risk and volatility, RVPH or VTGN? Reviva Pharmaceuticals has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. SummaryReviva Pharmaceuticals beats VistaGen Therapeutics on 10 of the 16 factors compared between the two stocks. Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVPH vs. The Competition Export to ExcelMetricReviva PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.11M$2.42B$5.44B$9.65BDividend YieldN/A1.78%3.99%4.14%P/E Ratio-0.5319.8930.0425.06Price / SalesN/A423.57373.4277.08Price / CashN/A165.0335.9458.58Price / Book20.954.158.125.67Net Income-$29.92M$31.61M$3.25B$265.39M7 Day Performance-3.81%0.57%0.96%2.54%1 Month Performance11.26%2.67%2.69%1.89%1 Year Performance-50.72%4.41%28.08%24.09% Reviva Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVPHReviva Pharmaceuticals2.7944 of 5 stars$0.42-2.3%$9.00+2,048.0%-46.9%$20.11MN/A-0.535Negative NewsUpcoming EarningsShort Interest ↑Gap UpVTGNVistaGen Therapeutics0.868 of 5 stars$3.19+3.6%N/A-15.2%$89.81M$490K-1.9240News CoverageEarnings ReportUpcoming EarningsGap UpHigh Trading VolumeORMPOramed Pharmaceuticals0.5149 of 5 stars$2.21+2.3%N/A-5.9%$88.22M$1.34M-5.0210News CoveragePositive NewsUpcoming EarningsARTVArtiva Biotherapeutics2.6043 of 5 stars$2.96-17.8%$17.80+501.4%-76.6%$87.71M$250K0.0081Earnings ReportXBITXBiotech0.9658 of 5 stars$2.82-1.7%N/A-52.8%$87.50M$4.01M-2.19100Positive NewsUpcoming EarningsENTXEntera Bio1.9608 of 5 stars$2.06+10.8%$10.00+385.4%+7.1%$84.54M$180K-7.9220Positive NewsGap UpHigh Trading VolumeMISTMilestone Pharmaceuticals2.0396 of 5 stars$1.55-1.9%$7.00+351.6%+13.5%$84.47M$1M-1.9930Upcoming EarningsCABACabaletta Bio1.8562 of 5 stars$1.69+1.8%$14.43+753.8%-76.3%$84.23MN/A-0.6750News CoverageEarnings ReportUpcoming EarningsQNCXQuince Therapeutics3.0251 of 5 stars$1.80-2.7%$8.00+344.4%+142.0%$84.12MN/A-1.2960Upcoming EarningsAnalyst ForecastShort Interest ↑JMACMaxpro Capital AcquisitionN/A$6.23+1.3%N/A+3,610.9%$83.66MN/A0.002,021Gap DownEXOZeXoZymesN/A$9.93-0.5%N/AN/A$83.51M$70K0.0029News Coverage Related Companies and Tools Related Companies VTGN Alternatives ORMP Alternatives ARTV Alternatives XBIT Alternatives ENTX Alternatives MIST Alternatives CABA Alternatives QNCX Alternatives JMAC Alternatives EXOZ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RVPH) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
